ADOMEGLIVANT

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C32H36F3NO4
Molecular Weight	555.6277
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC(O[C@@H](CCC(F)(F)F)C2=CC=C(C=C2)C(=O)NCCC(O)=O)=CC(C)=C1C3=CC=C(C=C3)C(C)(C)C

InChI

InChIKey=FASLTMSUPQDLIB-MHZLTWQESA-N

InChI=1S/C32H36F3NO4/c1-20-18-26(19-21(2)29(20)23-10-12-25(13-11-23)31(3,4)5)40-27(14-16-32(33,34)35)22-6-8-24(9-7-22)30(39)36-17-15-28(37)38/h6-13,18-19,27H,14-17H2,1-5H3,(H,36,39)(H,37,38)/t27-/m0/s1

HIDE SMILES / InChI

Description
Sources: http://en.pharmacodia.com/web/drug/1_22370.html | https://www.ncbi.nlm.nih.gov/pubmed/26681715 | https://www.ncbi.nlm.nih.gov/pubmed/28371155

Adomeglivant, also known as LY2409021, is a potent and selective glucagon receptor antagonist. Adomeglivant lowers blood glucose in healthy people and in those with type 2 diabetes. Blockade of glucagon signalling in patients with type 2 diabetes is well tolerated and results in substantial reduction of fasting and postprandial glucose with minimal hypoglycaemia, but with reversible increases in aminotransferases. Adomeglivant had been in phase II clinical trials by Eli Lilly for the treatment of type 2 diabetes mellitus. However, this research has been discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glucagon receptor 4 Target ID: CHEMBL1985 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25656305 \| https://professional.diabetes.org/abstract/glucose-lowering-efficacy-ly2409021-small-molecule-glucagon-receptor-antagonist-obob-mice	Antagonist 2778		6.66 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 259 Sources: https://clinicaltrials.gov/ct2/show/NCT02091362 https://clinicaltrials.gov/ct2/show/NCT00871572	Primary		Phase II 1132	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00AC7L	https://www.1pchem.com/search?query=1P00AC7L
AbovChem LLC	HY-19904
Chem Scene	CS-5729	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-5729
Compound Cloud	91933867
MedChem Express	HY-19904	https://www.medchemexpress.com/search.html?q=HY-19904&ft=&fa=&fp=
MolPort	MolPort-046-417-271	https://www.molport.com/shop/molecule-link/MolPort-046-417-271
Molnova	M12058	https://www.molnova.com/en/serch-list.html?keywords=M12058
MuseChem	I001829	https://www.musechem.com/product/I001829.html
eMolecules	275036906	https://orderbb.emolecules.com/search/#?query=275036906
eMolecules	303170678	https://orderbb.emolecules.com/search/#?query=303170678
eMolecules	89942146	https://orderbb.emolecules.com/search/#?query=89942146
mcule	MCULE-9754046865	https://mcule.com/MCULE-9754046865/

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Type 2 Diabetes Mellitus: single daily dose of 20 milligrams (mg) Adomeglivant (LY2409021) administered orally in 1 of 2 treatment periods.

Route of Administration: Oral

In Vitro Use Guide

Adomeglivant (LY2409021) was identified as a potent and selective antagonist that inhibits the human glucagon receptor (hGCGR) with a Ki of 6.66 +/- 0.64 nM and the mouse GCGR with a Ki of 75.3 +/-11.4 nM.

Name

Type

Language

ADOMEGLIVANT

Official Name

English

ADOMEGLIVANT, (-)-

Common Name

English

.BETA.-ALANINE, N-(4-((1S)-1-((4'-(1,1-DIMETHYLETHYL)-2,6-DIMETHYL(1,1'-BIPHENYL)-4-YL)OXY)-4,4,4-TRIFLUOROBUTYL)BENZOYL)-

Systematic Name

English

ADOMEGLIVANT [USAN]

Common Name

English

Adomeglivant [WHO-DD]

Common Name

English

3-(4-((1S)-1-((4'-TERT-BUTYL-2,6-DIMETHYLBIPHENYL-4-YL)OXY)-4,4,4- TRIFLUOROBUTYL)BENZAMIDO)PROPANOIC ACID

Systematic Name

English

LY-2409021

Code

English

LY2409021

Code

English

adomeglivant [INN]

Common Name

English

Code System Code Type Description

SMS_ID

100000174616